Keros Therapeutics (NASDAQ:KROS) is a biotechnology company focused on the development of innovative treatments for hematological and musculoskeletal disorders with high unmet medical needs. Through its pioneering research in transforming growth factor-beta (TGF-beta) family proteins, Keros aims to address diseases characterized by low blood cell counts, bone disorders, and muscular dystrophies. Their portfolio includes flagship projects such as KER-050 for the treatment of anemia and thrombocytopenia, and KER-047 designed to target fibrodysplasia ossificans progressiva and anemia of chronic disease. The company's objective is to leverage its deep understanding of TGF-beta protein mechanisms to advance a pipeline of novel therapeutics that can significantly improve patient outcomes and quality of life.